Unidirectional uptake of enkephalins at the blood-tissue interface of the blood-cerebrospinal fluid barrier: a saturable mechanism.
The cellular uptake at the blood-tissue interface of the blood-cerebrospinal fluid (CSF) barrier to tyrosyl-3,5-[3H]enkephalin-[5-L-leucine] (abbreviated to Leu-enkephalin) and of its synthetic analogue D-alanine2-tyrosyl-3,5-[3H]enkephalin-[5-D-leucine] (abbreviated to D-Ala2-D-Leu5-enkephalin) was studied in the isolated perfused choroid plexuses from the lateral ventricles of the sheep, using the rapid (less than 30 s), single circulation, paired-tracer dilution technique, in which D-[14C]-mannitol serves as an extracellular marker. Cellular uptake of peptides was estimated by directly comparing venous dilution profiles of [3H] and [14C] radioactivities in the absence and presence of unlabelled peptide, the N-terminal amino acid (L-tyrosine), the typical L-transport system substrate, 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH) and the inhibitor of aminopeptidase activity, bacitracin. The cellular uptake of both enkephalins was strongly (65-76%) but not completely inhibited by the addition of 5 mM unlabelled peptide to the bolus; the self-inhibition was significantly higher for D-Ala2-D-Leu5-enkephalin than for Leu-enkephalin. The addition to the bolus of L-tyrosine (5 mM), BCH (10 mM) or bacitracin (2 mM) reduced the 3H-radioactivity uptake by the choroid plexus of both enkephalins by 20-40%, the degree of inhibition being greater for [3H]-Leu-enkephalin than for its analogue. It is concluded that during single passage of enkephalins through the choroid plexus circulation, unidirectional uptake at the blood-tissue interface of the blood-CSF barrier consists of two components; a saturable component, which represents uptake of the intact peptide by the choroid epithelium, and a non-saturable component, which reflects enzymatic degradation of peptide in the blood and/or at the barrier, with a liberation of the N-terminal tyrosyl residue. Higher penetration of the blood-CSF barrier by D-Ala2-D-Leu5-enkephalin can be attributed to its greater resistance to hydrolysis.
D000818:Animals; D001414:Bacitracin / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D002250:Carbon Radioisotopes; D002831:Choroid Plexus / Q000378:metabolism*; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives* / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D066298:In Vitro Techniques; D007700:Kinetics; D008353:Mannitol / Q000378:metabolism; D012756:Sheep; D014316:Tritium
D002250:Carbon Radioisotopes; D014316:Tritium; D001414:Bacitracin; D008353:Mannitol; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; C030279:enkephalinamide-Leu, Ala(2)-